19 Mar Cholesterol Vs Homocysteine: Who is actually guilty?
You must have all heard that Cholesterol kills. But how many of you know Homocysteine, and its effects when its levels are high?
This is a misunderstood but critical marker, which is indicated as a risk factor for infraction, cancer and strokes.
Only one in one hundred biochemical tests performed today examine this high diagnostic value marker.
Dr. Kilmer Mc Cully, focused on this for the first time in the ‘70s. He was a researcher at the University of Harvard, and following repeated experiments on animals, he demonstrated that high Homocysteine levels was the cause of death. However, his publication was met with derision, and he lost his position at the University.
Almost twenty years had to pass to recognize the validity of his work.
Now, thousands of studies have confirmed Mc Cully’s initial view, that Homocysteine is an independent risk factor for cardiovascular Diseases. It has now been demonstrated that high levels of Homocysteine increase significantly the risk of stroke, when if heart diseases is already present, high levels of Homocysteine increase the risk of death from any cause.
Homocysteine is a toxic molecule. It is the result of methionine’s metabolism, an amino acid that contains sulfur. In some people with genetic deficiencies of certain enzymes, Homocysteine is not excreted by blood, leading in too early, extensive atherosclerosis, and they usually die due to infraction or stroke before adulthood.
Homocysteine causes damage inside arteries, as well as atherosclerosis, not only in the cases of genetic homocystinuria, but also in the general population.
This happens because Homocysteine is not adequately decomposed when it occurs as a product of burning if there also a deficiency of Vitamin B6 and Β12, folic acid, and zinc, as well as other secondary nutrients.
High Homocysteine levels have been associated with cancer, dementia (Alzheimer’s), osteoporosis, Parkinson’s disease, depression, chronic fatigue, fibromyalgia, diabetic retinopathy (blindness), thyroid deficiencies, inflammatory bowel disease and many other diseases.
In 1997, scientists published an article in the peer-reviewed medical journal “New England Journal of Medicine” went that far to state that high Homocysteine is “the most potent modifiable predictor of overall mortality (death from any cause) and cardiovascular mortality (infarction – stroke) in patients with coronary heart disease (heart vessels disease)”.
Typical checkups ignore the measurement of Homocysteine, as well as other significant health markers. Resistance to change according to new scientific evidence is huge. Even more when it comes to adopting new treatment strategies and approaches. Less than one in one hundred doctors embraces the new scientific data, and much less of them use them.
High homocysteine functions as a warning sign that our body does not methylate properly. Our body depends on methyliosis (transfer of a methyl group from one molecule to another) for its more critical functions in each cell of our body.
It is detoxified from carcinogens and other poisons, it repairs the damaged genetic material of cells (DNA), forms new health cells, creates valuable anti-aging hormones.
When our ability to methylate is damaged, all these important functions are prevented, leading to accelerated aging and degenerative diseases, as those mentioned in the present article.
This makes insufficient methylation one of the main predictable causes of immature aging and disease.
What to look for
Make sure the diet you choose is rich in vitamins and trace elements, choose foods with high nutritional value, natural foods and fruits, avoid all processed carbohydrates.
Studies have demonstrated that processed foods are deprived of B complex vitamins, which means that homocysteine is at higher levels as compared to the past in the average person.
Put your body in motion. Exercise, even a simple walk, can greatly help.
Smoking, hypertension, alcohol and too much coffee are also implicated as risk factors.
Ask your doctor to check your levels of homocysteine.
The correlation between Homocysteine and heart attacks seems more accurate than the correlation between Cholesterol and heart attacks. It is also worth noting that Homocysteine levels are increased with increasing age, while to the contrary, cholesterol levels decrease during the last decades of our lives.
The inclusion of this marker is of major importance in preventive examinations. According to the American Heart Association, its normal value is 6.3 μmol/L.
I wish all the best
Dr. Nikoleta Koini, M.D.
Doctor of Functional, Preventive, Anti-ageing and Restorative Medicine.
Diplomate and Board Certified in Anti-aging, Preventive, Functional and Regenerative Medicine from A4M (American Academy in Antiaging Medicine).
“Homocysteine metabolism”. Annual Review of Nutrition. 19: 217–246. doi:10.1146/annurev.nutr.19.1.217. PMID 10448523.
Champe, PC and Harvey, RA. “Biochemistry. Lippincott’s Illustrated Reviews” 4th ed. Lippincott Williams and Wilkins, 2008
Nelson, D. L.; Cox, M. M. “Lehninger, Principles of Biochemistry” 3rd Ed. Worth Publishing: New York, 2000. ISBN 1-57259-153-6.
Sibrian-Vazquez M, Escobedo JO, Lim S, Samoei GK, Strongin RM (January 2010). “Homocystamides promote free-radical and oxidative damage to proteins”. Proc. Natl. Acad. Sci. U.S.A. 107 (2): 551–4. doi:10.1073/pnas.0909737107. PMC 2818928Freely accessible. PMID 20080717.
Agnati, LF; Ferré, S; Genedani, S; Leo, G; Guidolin, D; Filaferro, M; Carriba, P; Casadó, V; Lluis, C; Franco, R; Woods, AS; Fuxe, K (Nov 2006). “Allosteric modulation of dopamine D2 receptors by homocysteine.”. Journal of Proteome Research. 5 (11): 3077–83. doi:10.1021/pr0601382. PMID 17081059.
Nygård, O; Vollset, SE; Refsum, H; Stensvold, I; Tverdal, A; Nordrehaug, JE; Ueland, M; Kvåle, G (Nov 15, 1995). “Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study.”. JAMA: the Journal of the American Medical Association. 274 (19): 1526–33. doi:10.1001/jama.274.19.1526. PMID 7474221.
Refsum, H; Nurk, E; Smith, AD; Ueland, PM; Gjesdal, CG; Bjelland, I; Tverdal, A; Tell, GS; Nygård, O; Vollset, SE (June 2006). “The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease.”. The Journal of Nutrition. 136 (6 Suppl): 1731S–1740S. PMID 16702348.
The Doctor’s Doctor: Homocysteine
Nutritionals Canada > Optimal blood test values Retrieved on July 9, 2009
Derived from molar values using molar massof 135 g/mol
Cattaneo, M (February 1999). “Hyperhomocysteinemia, atherosclerosis and thrombosis.”. Thrombosis and haemostasis. 81 (2): 165–76. PMID 10063987.
Morris, MS (July 2003). “Homocysteine and Alzheimer’s disease.”. Lancet neurology. 2 (7): 425–8. doi:10.1016/s1474-4422(03)00438-1. PMID 12849121.
Smach, MA; Jacob, N; Golmard, JL; Charfeddine, B; Lammouchi, T; Ben Othman, L; Dridi, H; Bennamou, S; Limem, K (2011). “Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer’s disease or dementia: a case control study.”. European neurology. 65 (5): 270–8. doi:10.1159/000326301. PMID 21474939.
Smith, AD; Smith, SM; de Jager, CA; Whitbread, P; Johnston, C; Agacinski, G; Oulhaj, A; Bradley, KM; Jacoby, R; Refsum, H (Sep 8, 2010). “Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.”. PLoS ONE. 5 (9): e12244. doi:10.1371/journal.pone.0012244. PMC 2935890Freely accessible. PMID 20838622.
Dietrich-Muszalska, A; Malinowska, J; Olas, B; Głowacki, R; Bald, E; Wachowicz, B; Rabe-Jabłońska, J (May 2012). “The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients.”. Neurochemical research. 37 (5): 1057–62. doi:10.1007/s11064-012-0707-3. PMC 3321271Freely accessible. PMID 22270909.
McLean, RR; Jacques, PF; Selhub, J; Tucker, KL; Samelson, EJ; Broe, KE; Hannan, MT; Cupples, LA; Kiel, DP (May 13, 2004). “Homocysteine as a predictive factor for hip fracture in older persons.”. The New England Journal of Medicine. 350 (20): 2042–9. doi:10.1056/NEJMoa032739. PMID 15141042.
JB; Dhonukshe-Rutten, RA; Pluijm, SM; van der Klift, M; de Jonge, R; Lindemans, J; de Groot, LC; Hofman, A; Witteman, JC; van Leeuwen, JP; Breteler, MM; Lips, P; Pols, HA; Uitterlinden, AG (May 13, 2004). “Homocysteine levels and the risk of osteoporotic fracture.”. The New England Journal of Medicine. 350 (20): 2033–41. doi:10.1056/NEJMoa032546. PMID 15141041.
Jager, A; Kostense, PJ; Nijpels, G; Dekker, JM; Heine, RJ; Bouter, LM; Donker, AJ; Stehouwer, CD (Jan 2001). “Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study.”. Arteriosclerosis, thrombosis, and vascular biology. 21 (1): 74–81. doi:10.1161/01.ATV.21.1.74. PMID 11145936.
Chalcraft, Kenneth R.; Lee, Richard; Mills, Casandra; Britz-McKibbin, Philip. “Virtual Quantification of Metabolites by Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry: Predicting Ionization Efficiency Without Chemical Standards”. Analytical Chemistry. 81 (7): 2506–2515. doi:10.1021/ac802272u.
Allen, Milton J.; Steinman, Harry G. “The Electrolytic Reduction of Homocystine at a Controlled Reference Potential”. Journal of the American Chemical Society. 74 (15): 3932–3933. doi:10.1021/ja01135a502.
Boudi, Brian F. “Noncoronary Atherosclerosis”. Medscape.
Homocysteine and folate levels as risk factors for recurrent early pregnancy lossMartí-Carvajal, AJ; Solà, I; Lathyris, D (January 15, 2015). “Homocysteine-lowering interventions for preventing cardiovascular events”. Heart Group. Cochrane Database of Systematic Reviews. John Wiley & Sons (1): Art. No. CD006612. doi:10.1002/14651858.CD006612.pub4. Retrieved 18 January 2015 – via The Cochrane Library. (subscription required (help)).
Homocysteine and Neural Tube Defects: An Overview Exp Biol Med (Maywood) April 2001 vol. 226 no. 4 243-270